FLT3 and acute myeloid leukemia: In a recent study, the FLT3 kinase inhibitor, AC220, was used to treat FLT3-positive AML cells, and was found to suppress expression of a subset of DNA repair proteins, thus causing synthetic lethal effects when administered with olaparib.